Monkasta (Montelukast)

Montelukast, the active ingredient in Monkasta, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It works by blocking cysteinyl leukotriene receptors, helping to prevent bronchoconstriction and airway inflammation. The medication is indicated for the long‑term control of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in both adult and pediatric patients.

GNH USA supplies Monkasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monkasta (montelukast) acts on the leukotriene pathway to manage several respiratory conditions. - Asthma: improves long‑term control of symptoms and reduces frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing during or after physical activity.

Montelukast is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: transient symptoms. - Cough: occasional dry cough. - Abdominal pain: mild discomfort. - Diarrhoea: loose stools. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Allergic reactions: including angio‑edema and anaphylaxis. - Mood changes: depression, suicidal thoughts. - Hepatic dysfunction: elevated liver enzymes. - Stevens‑Johnson syndrome: severe skin eruption. - Churg‑Strauss syndrome: vasculitis with eosinophilia.

When prescribing Monkasta, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: assess risk‑benefit as safety data are limited. - Lactation: monitor infant for possible effects if the mother is nursing. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant asthma therapy: ensure patients continue inhaled corticosteroids if prescribed. - Age considerations: dosage adjustments may be required for pediatric patients. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Montelukast may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: induces metabolism, reducing montelukast plasma levels. - Rifampicin: strong enzyme inducer that may lower therapeutic effect. - St. John’s wort: may decrease drug exposure through CYP3A4 induction.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): potential for increased neuropsychiatric side effects. - Warfarin: monitor INR as montelukast may affect anticoagulation. - Theophylline: observe for additive bronchospasm control effects.